Latest End point of clinical trials Stories
Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash.
An Italian study of more than 1,300 patients finds those with good prognostic factors fair about the same, regardless of their treatment. Raleigh, NC (PRWEB)
Latest Data from Large Subgroup of Patients Shows that the Combination of ThermoDox® and Optimized RFA Provides a Statistically Significant Survival Improvement of Over 50% LAWRENCEVILLE,
Topline Data Will Be Presented at Biotech Showcase HEIDELBERG, Germany, Jan.
Highlights Include ICT-107 Results to Date, Ongoing Data Analyses and Phase III Planning LOS ANGELES, Jan. 9, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
SUNNYVALE, Calif., Jan. 7, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML).
Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range.
A recent study featured in the latest issue of The Oncologist shows that active smoking greatly diminishes patients’ chances of responding to chemotherapeutic treatment for renal cell carcinoma
- A hairdresser.